BIOCHEM PHARMACOL 润色咨询

BIOCHEMICAL PHARMACOLOGY

出版年份:1958 年文章数:5668 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:3.4% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2025-06-29 ms6000000270780569 来自广西

    WE十天了,咋回事,要不要写信催催 ?

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2025-07-11 匿名用户

    必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2025-07-01 匿名用户

    通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2025-04-14 123456八成的 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:心血管
    经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2024-01-26 ms4000000706495698 来自上海

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:肝脏药理
    经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2024-02-03 ms7000001842576921 来自上海

    1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2024-06-02 ms1000000537292872 来自河北省

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2024-09-04 ms1000001788820000 来自上海

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:医学
    经验分享:3.8投稿,3.14 with editor,
    一个多月后under review
    后面四月底评审结束
    5.8 dip
    5.12 reverse
    5.20 resubmitted
    5.28 with editor
    6.3 under review
    6.7评审结束
    6.11 二返(半月)
    后面又经历了催稿对接最后online。

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2024-12-05 ms5000000995859510 来自山西省

    请问这个杂志with editor之后dip是不是就快拒了呀

    6

    展开6条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2271378, encodeId=0e0122e13781c, content=WE十天了,咋回事,要不要写信催催 ?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e028335127, createdName=ms6000000270780569, createdTime=Sun Jun 29 21:56:38 CST 2025, time=2025-06-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2272901, encodeId=bcbb22e290103, content=必须要机构邮箱,补充材料只能是视频或者音频,图表均不可以作为补充材料。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Fri Jul 11 09:16:00 CST 2025, time=2025-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2271627, encodeId=52ab22e162719, content=通讯作者的电子邮件地址未反映与研究型机构的隶属关系,则手稿将不被考虑在 Biochemical Pharmacology 上发表。机构电子邮件地址必须包含在通讯作者在在线投稿系统 Editorial Manager 中的注册个人资料中。或者,提交的文章必须附有一份单独的英文声明,由手稿来源机构负责研究活动的官员签署,证明通讯作者隶属于研究机构。该声明还必须包括官员的电子邮件地址和完整的联系信息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 01 17:43:42 CST 2025, time=2025-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2260429, encodeId=c33c22604293e, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管<br>经验分享:最新写了一篇综述,投到这个杂志。没进入审稿,直接给的DIP。但是编辑给了一些格式的意见,让修改后,重新提交。已经提交,准备等审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzB8KTw5fRddzkAb6hN75KWHXVlmRnX8Eoug6WeMSwYsdm2O7oSrbf0tg7grLicrfNs7LNrTNhHNg/132, createdBy=f9d82046571, createdName=123456八成的, createdTime=Mon Apr 14 16:45:10 CST 2025, time=2025-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肝脏药理<br>经验分享:1.16晚上投稿,submiteed一周,1.23with editor,1.26under review,感觉最近进度是有点慢的,不如官网宣传的3天,共大家参考。前期投稿分享:一投的pharmcological research,当天桌拒,建议转投biomedicine&pharmcptherapy,这个杂志之前预警过(不太理解),没投了。二投的中国药理学报(APS),当天桌拒,然后投了这个杂志,希望顺利吧!也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2185705, encodeId=16002185e0521, content=1.25submitted,2.1with editor,2.2decision in progress,求助友友们我是不是凉凉了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Sat Feb 03 20:10:45 CST 2024, time=2024-02-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2207937, encodeId=9652220e93751, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:1.3 submitted,1.7 with editor,1.11 under review,2.8 时间变动状态不变 2.12,评审结束 2.22 DIP 2.24 reverse(1个月) 3.22 resubmitted 3.26 with editor 4.1 under review 4.3 评审结束 4.6 二返(半月),4.12 resubmitted, 4.19催稿,4.21接收,4.25 online。投稿共耗时4个月,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44f99168202, createdName=ms1000000537292872, createdTime=Sun Jun 02 17:13:38 CST 2024, time=2024-06-02, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2224109, encodeId=4c28222410922, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:3.8投稿,3.14 with editor,<br>一个多月后under review<br>后面四月底评审结束 <br>5.8 dip <br>5.12 reverse<br>5.20 resubmitted <br>5.28 with editor <br>6.3 under review <br>6.7评审结束 <br>6.11 二返(半月)<br>后面又经历了催稿对接最后online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820000, createdTime=Wed Sep 04 23:18:38 CST 2024, time=2024-09-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2240886, encodeId=31322240886ed, content=请问这个杂志with editor之后dip是不是就快拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5a59183231, createdName=ms5000000995859510, createdTime=Thu Dec 05 08:37:19 CST 2024, time=2024-12-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2256436, encodeId=ddb7225643687, content=请问with editor之后decision in process了 是要被拒了嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6b9575808, createdName=ms3000000153133629, createdTime=Mon Mar 17 13:33:46 CST 2025, time=2025-03-17, status=1, ipAttribution=江苏省)]
    2025-03-17 ms3000000153133629 来自江苏省

    请问with editor之后decision in process了 是要被拒了嘛

    2

    展开2条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分